Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

A promising strategy to overcome drug resistance developed by blood cancer cells

In a collaborative study published in Blood Advances, a research group led by Beate Heissig at Juntendo University and Yousef Salama at An Najah University report a strategy to overcome drug resistance developed by blood cancer cells.

27 Mar 2020

Gero uses AI platform to identify potential anti-COVID-19 drugs

Gero, the leader in AI-driven drug discovery, has used its AI platform to identify the potential anti-COVID-19 drugs. Six of them have been approved, three were withdrawn, and the other nine have been already tested in clinical trials for other indications.

25 Mar 2020

Genetic test could help doctors to identify patients with ultra high risk multiple myeloma

A new genetic test could help doctors pick out patients with the bone marrow cancer multiple myeloma who are at 'ultra high risk' of their cancer progressing aggressively early on.

10 Mar 2020

Single gene cluster loss promotes initiation and progression of multiple myeloma in mice

The loss of one copy of the miR15a/miR16-1 gene cluster promoted initiation and progression of multiple myeloma in mice.

20 Feb 2020

Research reveals novel way to treat cancers using CAR T cell therapy

Too many patients with cancers like multiple myeloma relapse after treatment. This grim reality motivated researchers at Huntsman Cancer Institute at the University of Utah to try to improve the depth and durability of treatment response in multiple myeloma through a new cancer cell targeting mechanism.

10 Feb 2020

New discovery could enable scientists to fine-tune activity of cancer-killing immune cells

A discovery by University of North Carolina Lineberger Comprehensive Cancer Center researchers could allow scientists to fine-tune genetically engineered immune cells to heighten their killing power against tumors or to decrease their activity level in the case of severe side effects.

31 Jan 2020

IU researchers receive $3 million NIH grants to study cell functions in the bone marrow

More than $3 million from the National Institutes of Health will allow Indiana University Melvin and Bren Simon Cancer Center researchers to improve understanding of the complex system of how hematopoietic stem cells survive and sustain their function in the bone marrow.

31 Jan 2020

SU2C announces international team for fighting gastric cancer

Stand Up To Cancer announced today that an international team of experts will take a new approach to fighting the world's third-leading cause of cancer death -- stomach (or gastric) cancer.

28 Jan 2020

Daratumumab proves effective in patients with relapsed AL amyloidosis

There's a new treatment option available for patients with AL amyloidosis: daratumumab. Studied in a prospective clinical trial, only one of the two clinical trials of this agent in AL amyloidosis worldwide, researchers have found this anti-cancer drug to be well tolerated and effective in patients with relapsed AL amyloidosis when used with appropriate pre- and post-infusion medications.

27 Jan 2020

The Riney Family Multiple Myeloma Initiative to be established at Dana-Farber

Dana-Farber Cancer Institute will establish the Riney Family Multiple Myeloma Initiative to help improve outcomes and accelerate understanding of the underlying biology for the most challenging types of myelomas, cancers that form in a type of white blood cell called a plasma cell.

13 Jan 2020

Researchers discover a way to move precision immunotherapy forward for multiple myeloma

Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way to move precision immunotherapy forward by using genomics to inform immunotherapy for multiple myeloma, a blood cancer, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research, in December.

19 Dec 2019

New combination therapy can lead to durable responses in patients with multiple myeloma

An experimental, off-the-shelf immunotherapy that combines a targeted antibody and chemotherapy can lead to potentially durable responses in multiple myeloma patients whose disease has relapsed or is resistant to other standard therapies.

17 Dec 2019

Risk of specific genetic translocation is higher in patients of African ancestry, shows study

Multiple myeloma is a plasma cell cancer that is more common in patients of African American descent than of European American descent.

10 Dec 2019

$Novel agent opens up new treatment option for patients with refractory myeloma$

Novel agent opens up new treatment option for patients with refractory myeloma

A novel agent called Selinexor has opened up new options for the treatment of patients with refractory myeloma. This was the conclusion of a major international clinical trial in which also the Karl Landsteiner University of Health Sciences in Krems, Austria participated.

6 Dec 2019

Cancer patients have higher risk of cardiovascular death

A new study says that over 10% of patients with cancer die of unrelated cardiovascular disease (CVD) rather than their cancers.

25 Nov 2019

Risk of death from heart disease found to be higher in cancer patients

More than one in ten cancer patients do not die from their cancer but from heart and blood vessel problems instead, according to new research published in the European Heart Journal today. For some cancers, like breast, prostate, endometrial, and thyroid cancer, around half will die from cardiovascular disease (CVD).

25 Nov 2019

Fosun Pharma, MimiVax to jointly develop and commercialize SurVaxM therapy in U.S.

The inventors of a new and unique cancer immunotherapy developed at Roswell Park Comprehensive Cancer Center have announced a major step forward with that therapy, known as SurVaxM. MimiVax LLC principals Robert Fenstermaker, MD, and Michael Ciesielski, PhD, have announced that the company, spun off from Roswell Park in 2012, has entered into a China-exclusive licensing agreement for SurVaxM with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical Co. Ltd. based in Shanghai, China.

20 Nov 2019

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

A promising strategy to overcome drug resistance developed by blood cancer cells

Gero uses AI platform to identify potential anti-COVID-19 drugs

Genetic test could help doctors to identify patients with ultra high risk multiple myeloma

Single gene cluster loss promotes initiation and progression of multiple myeloma in mice

Research reveals novel way to treat cancers using CAR T cell therapy

New discovery could enable scientists to fine-tune activity of cancer-killing immune cells

IU researchers receive $3 million NIH grants to study cell functions in the bone marrow

SU2C announces international team for fighting gastric cancer

Daratumumab proves effective in patients with relapsed AL amyloidosis

The Riney Family Multiple Myeloma Initiative to be established at Dana-Farber

Researchers discover a way to move precision immunotherapy forward for multiple myeloma

New combination therapy can lead to durable responses in patients with multiple myeloma

Risk of specific genetic translocation is higher in patients of African ancestry, shows study

Novel agent opens up new treatment option for patients with refractory myeloma

Cancer patients have higher risk of cardiovascular death

Risk of death from heart disease found to be higher in cancer patients

Fosun Pharma, MimiVax to jointly develop and commercialize SurVaxM therapy in U.S.

New device separates malignant plasma cells from normal ones

New microfluidics device detects malignant multiple myeloma cells in blood

Gene-editing technique CRISPR trialed for first time as cancer treatment

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in